Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212744 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)
A Phase 2 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01212744 is a Phase 2 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 16 participants.
The verdict
NCT01212744, a Phase 2 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU.
Interventions
- DRUG rAvPAL-PEG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01212744
The ClinicalTrials.gov registry entry for NCT01212744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rAvPAL-PEG is the first listed.
NCT01212744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01212744 about?
NCT01212744 is a clinical study titled "Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)". The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU.
What is the current status of trial NCT01212744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2011-03. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01212744?
The interventions under investigation include: rAvPAL-PEG (DRUG).
Who is sponsoring clinical trial NCT01212744?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.